The risk of cytokine release syndrome (CRS) with CAR T cell administration in virologically suppressed patients is expected to be lower than that observed during treatment of malignancies, since Env is a non-self antigen and CRS is related to high (tumor) antigenic load. The gene discussed is ERVW-1; the disease is neoplasm.